NASHVILLE, TN, December 15, 2025 — Cencora, Inc. today announced it has entered into a definitive agreement to acquire TPG’s equity interest in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology. The transaction marks an important step for OneOncology and its practice partners, following significant physician-led investment and growth for the platform.

“We are pleased to advance our longstanding partnership with Cencora, who shares our commitment to supporting independent providers,” said Jeff Patton, M.D., Chief Executive Officer of OneOncology. “We are grateful for TPG’s support and partnership, which has enabled us to expand our capabilities as we seek to increase access to higher-quality care for more patients nationwide. As cancer care becomes increasingly complex, leveraging the significant expertise of Cencora across the healthcare landscape while still maintaining our independence will allow us to enhance the value we provide to practices, improving physicians’ ability to focus on delivering accessible and innovative care to their patients.”

Cencora’s expanded investment underscores a shared commitment to advancing specialty care and supporting independent physician practices. Together, they will seek to accelerate OneOncology’s ability to deliver significant value to physicians and their patients through growth investment, clinical innovation, shared services, and expanded technology capabilities.

Bob Mauch, President & CEO of Cencora said: “We are excited to accelerate our acquisition of OneOncology, which will advance our management services organization and aligns with our approach of making growth-oriented investments that support our pharmaceutical-centric strategy. Since our initial investment in OneOncology, the platform has grown substantially as its physician-led approach continues to attract leading practices and physicians, supporting patient access to high-quality care in local communities. With our recent acquisition of RCA, we look forward to building on both platforms’ research and clinical trial capabilities, advanced technology resources and strong physician leadership to drive unique value to our stakeholders.”

“We are proud to have partnered with OneOncology to support the leading platform advancing cancer care and improving patient outcomes and experiences every day,” said Kendall Garrison, Partner at TPG. “Since 2023, OneOncology has expanded its footprint, integrated leading, patient-focused practices into its national network, and accelerated initiatives to invest behind best-in-class, accessible care. We have been privileged to partner with Dr. Patton and the management team and are confident in the business' success with Cencora’s continued support,” added John Schilling, Co-Managing Partner of TPG Capital.